Cumambrin B Alleviates Sepsis-Associated Acute Lung Injury by Activating the Nrf2/HO-1 Pathway

Area of Science:

• Biomedical Science
• Pharmacology
• Cell Biology

Background:

• Sepsis-associated acute lung injury (SA-ALI) is a severe complication of infection, marked by excessive inflammation.
• Cumambrin B (CB), a natural sesquiterpene lactone, possesses known anti-inflammatory properties.
• The specific protective mechanisms of CB against SA-ALI are not well understood.

Purpose of the Study:

• To investigate the protective effects of Cumambrin B (CB) against sepsis-associated acute lung injury (SA-ALI).
• To elucidate the molecular mechanisms underlying CB's therapeutic actions in SA-ALI.

Main Methods:

• Sepsis-associated acute lung injury (SA-ALI) was induced in mice using lipopolysaccharide (LPS).
• CB's protective effects and mechanisms were evaluated in vivo (mice) and in vitro (LPS-induced RAW264.7 cells).
• Network pharmacology, mitochondrial function assays, and Western blotting were employed to analyze molecular pathways, including Nrf2/HO-1.

Main Results:

• CB significantly reduced lung tissue damage in a mouse model of SA-ALI.
• CB demonstrated potent anti-inflammatory and antioxidant activities, crucial for its protective effects.
• CB restored mitochondrial function and activated the Nrf2/HO-1 signaling pathway, which was essential for its anti-inflammatory and antioxidant actions.

Conclusions:

• Cumambrin B (CB) offers protection against sepsis-associated acute lung injury (SA-ALI).
• CB alleviates SA-ALI by mitigating oxidative stress and inflammation.
• Activation of the Nrf2/HO-1 pathway and restoration of mitochondrial function are key mechanisms for CB's therapeutic effects in SA-ALI.